Retrospective cohort study evaluated 11-year trends in insulin pump therapy outcomes in children with type 1 diabetes, suggesting the need for continuous education.
AIMS: Continuous subcutaneous insulin infusion (CSII) is standard care in paediatric type 1 diabetes (T1D). This study evaluated 11-year trends in CSII adoption, device evolution, indications, discontinuation, and metabolic outcomes in a paediatric diabetes centre. METHODS: We conducted a retrospective cohort study of children and adolescents with T1D followed from 2013 to 2024. Data included age at diagnosis and pump initiation, prior insulin regimen, device type, HbA1c, acute complications, and reasons for discontinuation or switching. Time to pump discontinuation was analysed using Cox regression. Device switching occurred in 21%, mostly to access newer features. CONCLUSIONS: CSII adoption increased substantially over the study period, accompanied by a shift toward hybrid closed-loop systems and stable metabolic outcomes. Early initiation at diagnosis was feasible and safe. These real-world findings highlight the importance of education, adherence support, and multidisciplinary care in optimizing long-term paediatric CSII use.
No takes yet. Share an insight, caveat, or question.
Anissa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: